Related Experiment Video
Updated: Jul 19, 2026
Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model
Published on: September 14, 2009
Coronary restenosis after implantation of drug-eluting stents
1Center for Cardiology and Vascular Intervention, Hamburg, Germany. schofer@center-for-cardiology.de
Insights
Drug-eluting stents (DES) significantly reduce restenosis compared to bare-metal stents. However, factors like incomplete coverage and uneven drug delivery can cause post-DES restenosis, with treatment outcomes needing further study.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Biomaterials Science
Background:
- Drug-eluting stents (DES) have markedly reduced restenosis rates compared to bare-metal stents.
- Despite advancements, restenosis after DES implantation remains a clinical challenge.
Purpose of the Study:
- To review the causes of restenosis following drug-eluting stent implantation.
- To discuss current understanding and treatment strategies for post-DES restenosis.
Main Methods:
- Review of randomized trials comparing DES and bare-metal stents.
- Analysis of factors associated with post-DES restenosis.
- Evaluation of existing evidence on the treatment of post-DES restenosis.
Main Results:
- DES significantly lower angiographic and clinical restenosis rates.
- Incomplete stent coverage, underexpansion, and focal antiproliferative agent delivery are linked to post-DES restenosis.
- Long-term outcomes for interventional treatment of post-DES restenosis are suboptimal and require further investigation.
Conclusions:
- While DES are highly effective, focal inadequate drug delivery is a key factor in restenosis.
- There is currently no established consensus on the optimal treatment for post-DES restenosis.
- Further research is essential to improve outcomes for patients experiencing restenosis after DES implantation.
Abstract:
Randomized trials comparing drug-eluting stents (DES) with bare-metal stents have shown that the former significantly reduce the incidence of angiographic and clinical restenosis into an unprecedented low, one-digit, range. However, post-DES restenosis is not zero. Next to incomplete coverage with DES of the vessel segment injured by balloon angioplasty, factors such as stent underexpansion, stent overexpansion, and nonuniform distribution of stent struts have been associated with post-DES restenosis. Current evidence suggests that inadequate, though predominantly focal, delivery of the antiproliferative agent (sirolimus or paclitaxel) into the vessel wall is likely the common cause of post-DES restenosis. There is no consensus at present on how to treat post-DES restenosis. Long-term results reported to date on small numbers of patients undergoing interventional treatment for post-DES restenosis appear to be worse than outcomes observed after the index intervention, regardless of whether another DES was implanted or not, and warrant further study.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care